JP2010501596A5 - - Google Patents

Download PDF

Info

Publication number
JP2010501596A5
JP2010501596A5 JP2009525863A JP2009525863A JP2010501596A5 JP 2010501596 A5 JP2010501596 A5 JP 2010501596A5 JP 2009525863 A JP2009525863 A JP 2009525863A JP 2009525863 A JP2009525863 A JP 2009525863A JP 2010501596 A5 JP2010501596 A5 JP 2010501596A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
group
condition
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009525863A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010501596A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2007/001282 external-priority patent/WO2008025099A1/en
Publication of JP2010501596A publication Critical patent/JP2010501596A/ja
Publication of JP2010501596A5 publication Critical patent/JP2010501596A5/ja
Pending legal-status Critical Current

Links

JP2009525863A 2006-08-31 2007-08-31 抗体含有組成物を用いた非感染性の病状の処置および/または予防 Pending JP2010501596A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2006904752A AU2006904752A0 (en) 2006-08-31 Uses for Antibodies
PCT/AU2007/001282 WO2008025099A1 (en) 2006-08-31 2007-08-31 Treatment and/or prevention of non-infectious medical conditions using antibody-containing compositions

Publications (2)

Publication Number Publication Date
JP2010501596A JP2010501596A (ja) 2010-01-21
JP2010501596A5 true JP2010501596A5 (enExample) 2010-09-16

Family

ID=39135433

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009525863A Pending JP2010501596A (ja) 2006-08-31 2007-08-31 抗体含有組成物を用いた非感染性の病状の処置および/または予防

Country Status (8)

Country Link
US (2) US20100297140A1 (enExample)
EP (1) EP2061510B1 (enExample)
JP (1) JP2010501596A (enExample)
CN (1) CN101626784B (enExample)
AU (1) AU2007291891B2 (enExample)
DK (1) DK2061510T3 (enExample)
NZ (1) NZ575918A (enExample)
WO (1) WO2008025099A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2725035A1 (en) 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
ES2684696T3 (es) 2009-04-27 2018-10-04 Immuron Limited Preparación de inmunoglobulina enriquecida con anti-LPS para su uso en el tratamiento y/o la profilaxis de esteatohepatitis no alcohólica
JP2011026252A (ja) * 2009-07-27 2011-02-10 Kitasato Institute 上皮成長因子受容体に対する卵黄抗体およびその用途
AU2011290478B2 (en) 2010-08-17 2014-11-13 Hadasit Medical Research Services & Development Limited Anti-LPS enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder
PH12013501040A1 (en) 2010-11-23 2022-10-24 Pantheryx Inc Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications
US20140302034A1 (en) * 2010-12-08 2014-10-09 Stem Centrx, Inc. Novel modulators and methods of use
WO2012098256A1 (en) * 2011-01-21 2012-07-26 Université De La Méditerranée Aix - Marseille Ii Anti-cd146 auto-antibodies and uses thereof
DE102011006809A1 (de) 2011-04-05 2012-10-11 Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten
WO2013080050A2 (en) * 2011-11-30 2013-06-06 Universitaetsklinikum Erlangen Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
EP3065780A1 (en) 2013-11-04 2016-09-14 Pfizer Inc. Anti-efna4 antibody-drug conjugates
RO130965A8 (ro) * 2015-10-16 2017-06-30 Romvac Company S.A. Producerea şi utilizarea oului hiperimun personalizat () în tratamentul psoriazisului
US10792320B2 (en) * 2018-03-28 2020-10-06 Michael Alan Beller Methods for treatment of bladder dysfunction
US12263192B2 (en) 2019-02-26 2025-04-01 Pantheryx, Inc. Compositions for management of disorders of the gastrointestinal tract
US11319382B1 (en) 2021-06-28 2022-05-03 King Abdulaziz University Methods for producing and using IgY antibodies targeting the middle east respiratory syndrome coronavirus spike protein to treat or prevent MERS-CoV infection

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3911108A (en) * 1973-02-14 1975-10-07 Diamond Shamrock Corp Process of producing bovine milk products containing specific antibodies
AUPN642795A0 (en) * 1995-11-08 1995-11-30 Northfield Laboratories Pty Ltd Dairy compositions and methods of preparing same
KR20000048855A (ko) * 1996-10-02 2000-07-25 오비뮨, 인크. 닭의 난황 항체를 경구 투여하여 질병을 치료하는 방법
CN1304312A (zh) * 1998-01-19 2001-07-18 Dcv公司 治疗和预防关节炎和/或自身免疫疾病的组合物与方法
WO1999064069A1 (en) * 1998-06-10 1999-12-16 Ophidian Pharmaceuticals, Inc. Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease
CN1163511C (zh) * 1999-10-22 2004-08-25 徐永华 鸡卵黄抗白细胞介素-8抗体、制备方法及其应用
CN1303889A (zh) 1999-12-20 2001-07-18 陶氏康宁东丽硅氧烷株式会社 用于嵌件模塑或双模腔模塑的硅橡胶组合物
JP2005298332A (ja) * 2000-09-28 2005-10-27 Shibayagi:Kk 過剰自己抗体産生抑制物質、その製造法およびその使用方法
KR20040106298A (ko) * 2002-03-21 2004-12-17 아나디스 리미티드 불안정한 생활성 물질 및 포유동물 초유를 포함한 조성물,제조 및 치료 방법
CN1199672C (zh) 2002-04-17 2005-05-04 李永忠 一套预防与治疗癌症中成药
CN1377894A (zh) * 2002-04-23 2002-11-06 郭占军 蛋黄抗癌抗体制备方法及其应用
AU2002951409A0 (en) * 2002-09-16 2002-09-26 North Western Adelaide Health Services Methods for regulating cancer
JP4264894B2 (ja) * 2004-03-01 2009-05-20 三菱自動車工業株式会社 エアボックス付きグローブボックス
AU2005224081B2 (en) * 2004-03-12 2011-06-30 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
CA2584804A1 (en) * 2004-10-21 2006-05-04 The Penn State Research Foundation Eph receptor tumor biomarkers
WO2006083936A2 (en) * 2005-01-31 2006-08-10 Genentech, Inc. Anti-ephb2 antibodies and methods using same
CN101253198A (zh) 2005-08-29 2008-08-27 独立行政法人科学技术振兴机构 使用鸵鸟产生的抗体及其制备方法

Similar Documents

Publication Publication Date Title
JP2010501596A5 (enExample)
Abourehab et al. Alginate as a promising biopolymer in drug delivery and wound healing: A review of the state-of-the-art
Sachdeva et al. Chitosan nanoparticles-based cancer drug delivery: application and challenges
Vashist et al. Recent advances in hydrogel based drug delivery systems for the human body
US10441760B2 (en) Self-actuating chemomechanical devices for delivery and extended release of therapeutic agents in the gastrointestinal tract
Jawadi et al. Bio-inspired muco-adhesive polymers for drug delivery applications
Thapa et al. Application of sol–gels for treatment of gynaecological conditions—physiological perspectives and emerging concepts in intravaginal drug delivery
WO2017028777A1 (zh) 贻贝粘蛋白产品及其抑制粘膜炎症的应用
EA032034B1 (ru) Наночастицы двукратно дериватизованного хитозана и способы их получения и применения для переноса генов in vivo
JP2016515113A5 (enExample)
JP2019031521A5 (enExample)
CA3160114A1 (en) New multi-functional oligopeptides
JP2010500284A5 (enExample)
Lu et al. Supramolecular self-assembled hydrogel for antiviral therapy through glycyrrhizic acid-enhanced zinc absorption and intracellular accumulation
WO2013177927A1 (zh) 注射用埃索美拉唑钠冻干粉组合物及其制备方法
TWI482632B (zh) 醫藥用載體及使用該載體的藥物結構
US20180179543A1 (en) Device and method to treat esophageal disorders
CN102964335B (zh) 一种埃索美拉唑钠化合物及其制备方法和用途
CN106474472A (zh) 肿瘤曲妥珠单抗靶向anti‑miR‑21纳米粒子及其制备方法
GR20180100090A (el) Φαρμακευτικο σκευασμα σε μορφη γελης για ασθενεις με ηωσινοφιλικη οισοφαγιτιδα
Xu BIDIRECTIONAL THERMORESPONSIVE GRIPPERS FOR MACROMOLECULAR DRUG DELIVERY
Xiao et al. Emerging novel hydrogels application in oral and gastrointestinal diseases: design wet adhesive strategy towards possible mechanisms
AU2021349286B2 (en) Vaccine compositions for mucosal immune response
CN110917478B (zh) 一种宫颈hpv感染用药物缓释器
JP2014118361A5 (enExample)